Trial site
Arkhangelsk Clinical Oncological Dispensary
Arkhangelsk, 163045, RussiaNot linked to an institution yet
- 8running trials
- 2closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 22 trials
- Status
- Active, not recruiting7 trials
- Completed2 trials
- Recruiting1 trial
- Lead sponsor
- Eli Lilly and Company5 trials
- Bristol-Myers Squibb2 trials
- Jiangsu HengRui Medicine Co., Ltd.1 trial
- Mabscale, LLC1 trial
- pharmaand GmbH1 trial
Running trials
Recruiting
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
NCT05654454· Phase 3· Mabscale, LLC· Source
Contact: Chapko
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Active, not recruiting
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458· Phase 3· Bristol-Myers Squibb· Source
Active, not recruiting
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error